What the Federal Budget could mean for CSL (ASX:CSL) shares

How shares in Australia's only vaccine manufacturer CSL Limited (ASX: CSL) might be affected by 2 key Federal Budget initiatives.

| More on:
a doctor looking up at question marks

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Federal Budget has hit the headlines, and one ASX 200 biotech company might be affected by a number of measures within it.

Shares in CSL Limited (ASX: CSL), Australia's only manufacturer of COVID-19 vaccines, may be in for an interesting year due to 2 key government initiatives.

This year's Budget has granted an additional $1.9 billion of funding to vaccinate Australians. Though, most of the announced changes regard the Pfister-BioNTech and Modena vaccines instead of the AstraZeneca plc (LSE: AZN) vaccine which CSL produces.

Further, the government has incorporated a patent box into this year's Budget.

Let's take a look at what the 2021/22 Federal Budget might mean for CSL shares.

CSL could rejoice from Australia's patent box

The Australian Government is the latest to introduce a patent box to encourage investment in the country's biotech companies.

The patent box will see biotech and medical company incomes from products made with Australian patents taxed at a rate of 17%. That's a decrease from the current tax rate of 25% to 30%.

The Government believes the patent box will encourage companies to conduct their research and development in Australia, as well as keeping their patents here afterwards.

CSL chief scientific officer Dr Andrew Nash had this to say this morning in the Sydney Morning Herald:

[The patent box is] an important reform and will help to ensure that the Australia of the future can more easily turn good science into products, professions, and local, advanced medical manufacturing capacity. It is an especially significant boost to the policy environment as the country navigates its way out of the pandemic.

Boosting vaccine rollout

The Federal Budget also includes another $1.9 billion of funding for the vaccine rollout.

The $1.9 billion includes $777.8 million to be spent over the next 2 years for the administration of COVID-19 vaccinations. Another $510.8 million will go towards the National Partnership on the COVID-19 Response, which will see states and territories also administering vaccines.

The remaining funding will go towards implementing, monitoring, and reporting the vaccine rollout; vaccine distribution, logistics, and storage; and a campaign to advertise the vaccination program.

In challenging news for CSL shares, the Government appears to be more focused on using mRNA vaccines like Pfister-BioNTech and Moderna. Prime Minister Scott Morrison said the Government was "better utilising the available stock of AstraZeneca doses" while announcing it had entered agreements to purchase 30 million doses of the Pfizer BioNTech vaccine. 

While this sounds like the Government might be starting to step away from AstraZeneca, the company is likely not to be banking heavily on AstraZeneca, no matter which vaccine the majority of Australians receive.

As The Motley Fool Australia has previously reported, CSL's exposure to vaccines isn't substantial, and its potential earnings from the AstraZeneca vaccine are small compared to its other business initiatives.

The Federal Budget also includes funding for the Department of Industry, Science, Energy and Resources, which will work with the Department of Health to set Australia up to manufacture mRNA vaccines.

It didn't state how much funding will go towards mRNA manufacturing due to commercial sensitivities.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »